Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 5
Submit an article Journal homepage
68
Views
6
CrossRef citations to date
0
Altmetric
Miscellaneous

Implications of the LIFE trial

Sunil Nadar University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK
,
Hoong Sern Lim University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK
&
Gregory YH Lip University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK
Pages 871-877 | Published online: 02 Mar 2005

Bibliography

  • DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359(9311):995–1003.
  • ANDERSON TJ, ELSTEIN E, HABER H, CHARBONNEAU F: Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J. Am. Coll Cardiol. (2000) 35(1):60–66.
  • GOTO K, FUJII K, ONAKA U, ABE I, FUJISHIMA M: Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension (2000) 36(4):575–580.
  • BUTLER R, MORRIS AD, STRUTHERS AD: Lisinopril improves endothelial function in chronic cigarette smokers. Clin. Sci. (2001) 101(1):53–58.
  • NIELSEN FS, ROSSING P, GALL MA et al.: Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Scand. Clin. Lab. Investig. (1997) 57(5):427–434.
  • ANDERSON T: Current trials on angiotensin-converting enzyme inhibitors and endothelial dysfunction. Can. 1. Cardiol. (1998) 14(Suppl. D):33D–34D.
  • KOHNO M, YOKOKAWA K, MINAMI M et al.: Plasma levels of nitric oxide and related vasoactive factors following long-term treatment with angiotensin-converting enzyme inhibitor in patients with essential hypertension. Metabol. Clin. Exp. (1999) 48(10):1256–1259.
  • RUSCHITZKA F, NOLL G, LUSCHER TF: Angiotensin converting enzyme inhibitors and vascular protection in hypertension. Cardiovasc. Pharmacol (1999) 34\(Suppl. 1):53–512.
  • MUNZEL T, KEANEY JF Jr: Are ACE inhibitors a 'magic bullet' against oxidative stress? Circulation (2001) 104(13):1571–1574.
  • KOH KK, BUI MN, HATHAWAY L et al: Mechanism by which quinapril improves vascular function in coronary artery disease. Am. J. Cardiol. (1999) 83(3):327–331.
  • MILLGARD J, HAGG A, SARABI M, LIND L: Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. 1. Hum. Hypertens. (1998) 12(8):511–516.
  • MANCINI GB, HENRY GC, MACAYA C et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation (1996) 94(3):258–265.
  • JAMES IM, DICKENSON EJ, BURGOYNE W et al.: Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. J. Hum. Hypertens. (1988) 2(1):21–25.
  • GUPTA RK, KJELDSEN SE, MOTLEY E,WEDER AB, ZWEIFLER AJ, JULIUS S: Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor. Cardiovasc. Pharmacol. (1991) 17(1):13–19.
  • IAKOVLEV VM, SEMENKIN AA, IUDIN SM et al.: [Effect of enalapril maleate on vascular endothelial function and platelet-endothelial interactions in patients with essential hypertension]. Ter. Ara. (2000) 72(1):40–44.
  • MANCINI GB: Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations. Clin. Invest. Med. (2000) 23(2):144–161.
  • •Good review of the literature on ACEIs.
  • QUASCHNING T, D'USCIO LV, SHAW S, GRONE HJ, RUSCHITZKA F, LUSCHER TF: Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension. J. Am. Soc. Nephrol. (2001) 12(11):2280–2287.
  • GOTO K, FUJII K, ONAKA U, ABE I, FUJISHIMA M: Angiotensin-converting enzyme inhibitor prevents age-related endothelial dysfunction. Hypertension (2000) 36(4):581–587.
  • QUASCHNING T, D'USCIO LV, SHAW S, LUSCHER TF: Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension (2001) 37(4):1108–1113.
  • MANCINI GB: Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations. Clin. Invest. Med. (2000) 23(2):144–161.
  • •Good review of the literature on ACEIs and endothelial dysfunction.
  • YUSUF S, SLEIGHT P, POGUE J: Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342:145-153.
  • Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet (2001) 358(9287):1033–1041.
  • SCHIFFRIN EL, PARK JB, INTENGAN HD, TOUYZ RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation (2000) 101(14):1653–1659.
  • MAKRIS TK, STAVROULAKIS GA, KRESPI PG et al: Fibrinolytic/haemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am. 1. Hypertens. (2000) 13(7):783–788.
  • LI-SAW-HEE FL, BEEVERS DG, LIP GY: Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int. J. Cardiol. (2001) 78(3):241–246.
  • JIMENEZ AM, MONTON M, GARCIA R et al.: Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. Cardiovasc. Pharmacol. (2001) 37(4):406–412.
  • LEVY PJ, YUNIS C, OWEN J, BROSNIHAN KB, SMITH R, FERRARIO CM: Inhibition of platelet aggregability by losartan in essential hypertension. Am. 1. Cardiol. (2000) 86(11):1188–1192.
  • LI P, FERRARIO CM, BROSNIHAN KB: Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. (1998) 32(2):198–205.
  • KALINOWSKI L, MATYS T, CHABIELSKA E, BUZKO W, MALINSKI T: Angiotensin II AT1 Receptor antagonists inhibit platelet adhesion; and aggregation by nitric oxide release. Hypertension (2002) 40:521–527.
  • •New insights on the function of ARBs.
  • YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. Med. (2000) 342(3):145–153.
  • •Important cardiovascular trial.
  • SVENSSON P, DE FAIRE U, SLEIGHT P, YUSUF S, OSTERGREN J: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension (2001) 38(6):E28–E32.
  • Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA (2002) 288(23):2998–3007.
  • LIP GY: Losartan and the meaning of life. J. Hum. Hypertens. (2002) 16:289–291.
  • HACKAM DG, ASHCROFT JS: Drug treatment of hypertension. BMJ(2003) 326(7392):764.
  • RUZICKA M, LEENEN FH: Combination therapy as first-line treatment of arterial hypertension. Can. J. Cardiol. (2002) 18(12):1317–1327.
  • NAKAMURA S, SASAKI 0, NAKAHAMA H, INENAGA T, KIMURA G: Left ventricular hypertrophy is a risk factor independent of hypertension in survival of hemodialyzed patients. Ren. Fail (2002) 24(2):175–186.
  • VERDECCHIA P, CARINI G, CIRCO A et al.: Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. I Jim. Coll. Cardiol. (2001) 38(7):1829–1835.
  • GHALI JK 3rd, LIAO Y, COOPER RS: Left Ventricular Hypertrophy in the Elderly. Am. J. Ceriatr. Cardiol. (1997) 6(6):38–49.
  • DE SIMONE G, VERDECCHIA P, PEDE S, GORINI M, MAGGIONI AP: Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension (2002) 40:470–476.
  • BLAKE J, DEVEREUX RB, HERROLD EM: Relation of concentric left ventricular hypertrophy and extra-cardiac target organ damage to supranormal left ventricular performance in established essential hypertension. Am. Cardiol (1988) 62:246–252.
  • •Important study in understanding the prognosis in LVH.
  • DEVEREUX RB, PALMIERI V, LIU JEet al.: Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. I Hypertens. (2002) 20(7):1445–1450.
  • WACHTELL K, PALMIERI V, OLSEN MH et al.: Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention For Endpoint (LIFE) Study. Circulation (2002) 106(2):227–232.
  • WACHTELL K, BELLA JN, ROKKEDAL J et al.: Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation (2002) 105(9):1071–1076.
  • NAKASHIMA Y, FOUAD FM, TARAZI RC: Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am.,/ Cardiol. (1994) 53:1044–1049.
  • GAUDIO C, TANZILI G, COLLATINA S, PAGNOTTA P, PAKNEJAD K, CAMPA PP: Evaluation of regression of left ventricular hypertrophy in hypertensive patients treated with captopril as assessed by magnetic resonance. Cardiologia (1992) 37:789–791.
  • SCHMIEDER RE, MARTUS P, KINGBEIL A: Reversal of left ventricular hyprtrophy in essential hypertension: a meta-analyses of randomised double blind studies. JAMA (1996) 275:1507–1513.
  • OLSEN MH, WACHTELL K, HERMANN KL et al.: Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am. Heart (2002) 144(3):530–537.
  • HAFFNER SM, LEHTO S, RONNEMMA T: Mortality from coronary heart disease in subjects with Type 2 diabetes and in non diabetic subjects with and without myocardial infarction. N Engl. Med. (1998) 339:229–234.
  • SOWERS JR, EPSTEIN M, FROHLICH ED: Diabetes, hypertension and cardiovascular disease; an update. Hypertension (2001) 37:1053.
  • AMERICAN DIABETES ASSOCIATION: Treatment of hypertension in adults with diabetes. Diabetes Care (2002) 25\(Suppl. 1):s71–s73.
  • LINDHOLM LH, IBSEN H, DAHLOF B et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359(9311):1004–1010.
  • BURCH S, OU N: Current indications for ACE inhibitors and HOPE for the future. Am.Manag. Care (2002) 8(5):478–490.
  • HALKIN A, KEREN G: Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am.j Med. (2002) 112(2):126–134.
  • LEJEMTEL TH, HOCHMAN JS, SONNENBLICK EH: Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction. Am. Coll Cardiol. (1995) 25(7, Suppl.):47S–51S.
  • UKPDS GROUP UPDS: Tight blood pressure control and rusk of macrovascular and microvascular complications in Type 2 diabetes. BMJ(1998) 317:713–720.
  • HANSSON L, LINDHOLM LH, NISKANEN L: Effect of angiotensin concerting enzyme inhibition compared to conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet (1999) 353:611–616.
  • AMERICAN DIABETES ASSOCIATION, NATIONAL INSTITUTE OF DIABETES DaKd: The prevention or delay of Type 2 diabetes. Diabetes Care (2002) 25:742–749.
  • BLOOM JM: Losartan for cardiovasculardisease in patients with and without diabetes in the LIFE study. Lancet (2002) 359:2201–2204.
  • LINDHOLM LH, DAHLOF B: The life study: authors reply. Lancet (2002) 359:2203–2204.
  • OPIE LH, PARVING HH: Diabetic nephropathy: can reno-protection be extrapolated to cardiovascular protection? Circulation (2002) 106:643–645.
  • HPS COLLABORATIVE GROUP: MRC/ BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360(9326):7–22.
  • •Important cardiovascular study.
  • GROVER SA, COUPAL L, ZOWALL H: Cost effectiveness of treating hyperlipidaemia in the presence of diabetes: who should be treated. Circulation (2000) 102:722–727.
  • MUNFORD RS: Statins and the acute phase response. N Engl. Med. (2001) 344:2016–2018.
  • •Important review on the effects of statins.
  • GERDTS E, BJORNSTAD H, TOFF S, DEVEREUX RB, OMVIK P: Impact of diastolic doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). .1 Hypertens. (2002) 20(6):1223–1229.
  • GERDTS E, OIKARINEN L, PALMIERI V et al: Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension (2002) 39(3):739–743.
  • OLSEN MH, WACHTELL K, AALKJAER C, DIGE-PETERSEN H, ROKKEDAL J, IBSEN H: Vasodilatory capacity and vascular structure in long-standing hypertension: a LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am. Hypertens. (2002) 15(5):398–404.
  • OIKARINEN L, NIEMINEN MS, VIITASALO M et al: Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. Hypertens. (2001) 19(10):1883–1891.
  • BEEVERS DG: Beta-blockers for hypertension: time to call a halt. 1 Hum. Hypertens. (1998) 12(12):807–810.

Websites

  • www.diabetes.ca/section_about/ general_clinicaltrials_asp_2003 THE CANADIAN DIABETIC ASSOCIATION: The DREAM and NAVIGATOR studies.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.